Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437437 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
A Phase 1 study of Tumors, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT00437437 is a Phase 1 study of Tumors that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 29 participants, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00437437, a Phase 1 study of Tumors, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate
Conditions Studied
Interventions
- DRUG Brivanib
Study Locations (3)
Massachusetts
- Dana-Farber Harvard Cancer Care - Boston
Michigan
- Wayne State University - Detroit
North Carolina
- Duke University Medical Center-Dept Of Medicine - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2000-05 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437437
The ClinicalTrials.gov registry entry for NCT00437437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (85% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Brivanib is the first listed.
NCT00437437 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00437437 about?
NCT00437437 is a clinical study titled "A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)". The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate
What is the current status of trial NCT00437437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2000-05. Estimated completion is 2013-02.
What conditions does trial NCT00437437 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00437437?
The interventions under investigation include: Brivanib (DRUG).
Who is sponsoring clinical trial NCT00437437?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00437437 being conducted?
This trial has 3 study locations across Massachusetts, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.